FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3007490411> ?p ?o ?g. }

• W3007490411 endingPage "34" @default.
• W3007490411 startingPage "34" @default.
• W3007490411 abstract "To determine the conversion and reversion rates of tuberculosis (TB) screening tests (Tuberculin Skin Test-TST, Interferon Gamma Release Assay-IGRA: T-SPOT.TB) during biologic treatment in patients with rheumatic diseases and negative baseline screening.This was a long-term, longitudinal cohort study of 50 patients with rheumatic diseases and negative baseline TB screening (TST: < 5 mm, negative T-SPOT.TB) treated with tumor necrosis factor inhibitors (TNFi) or other non-TNFi biologics. Patients were rescreened at a mean time of 1.4 (first rescreening) and 6.9 (second rescreening) years from baseline, with both assays. The conversion (negative to positive) and reversion (positive to negative) rate was calculated for each TB screening test.Fifty patients (mean age = 60 years) with various rheumatic diseases (rheumatoid arthritis: n = 24, spondyloarthropathies: n = 23, other: n = 3) were enrolled. During the first phase (baseline to first rescreening), all patients were treated with TNFi while during the second phase (first to second rescreening), TNFi (54%) and non-TNFi (46%) were used. Fifteen patients (30%) displayed conversion of at least 1 screening assay during follow-up (10 at the first and 5 at the second rescreening). This conversion rate was higher with TST (n = 11, 22% or 3.47/100 patient-years) compared to T-SPOT.TB (n = 4, 8% or 1.74/100 patient-years). Among the 10 converters at the first rescreening, 5 received isoniazid (INH) preventive therapy and 5 did not; an equal number of patients (3/5, 60%) reverted to negative with or without INH therapy. None of the patients developed active TB during follow-up (6.9 ± 1.0 years).Approximately one-third of patients with rheumatic diseases and negative baseline TB screening developed conversion of at least 1 screening test during long-term biologic treatment. This occurred most often with TST and was usually a transient event. These findings do not support routine serial TB retesting in biologic-treated patients with rheumatic diseases in the absence of TB risk factors." @default.
• W3007490411 created "2020-03-06" @default.
• W3007490411 creator A5000090464 @default.
• W3007490411 creator A5002807035 @default.
• W3007490411 creator A5003036878 @default.
• W3007490411 creator A5017412054 @default.
• W3007490411 creator A5027237191 @default.
• W3007490411 creator A5038678361 @default.
• W3007490411 creator A5059681860 @default.
• W3007490411 creator A5064152130 @default.
• W3007490411 creator A5071905620 @default.
• W3007490411 creator A5074911675 @default.
• W3007490411 date "2020-02-26" @default.
• W3007490411 modified "2023-10-12" @default.
• W3007490411 title "Conversion and Reversion Rates of Tuberculosis Screening Assays in Patients With Rheumatic Diseases and Negative Baseline Screening Under Long-Term Biologic Treatment" @default.
• W3007490411 cites W1543214463 @default.
• W3007490411 cites W1672832385 @default.
• W3007490411 cites W1925361523 @default.
• W3007490411 cites W1966993745 @default.
• W3007490411 cites W1972770515 @default.
• W3007490411 cites W1974402066 @default.
• W3007490411 cites W2006511071 @default.
• W3007490411 cites W2023585231 @default.
• W3007490411 cites W2038535814 @default.
• W3007490411 cites W2040463552 @default.
• W3007490411 cites W2044846394 @default.
• W3007490411 cites W2050121020 @default.
• W3007490411 cites W2079039349 @default.
• W3007490411 cites W2093042207 @default.
• W3007490411 cites W2096321772 @default.
• W3007490411 cites W2097362715 @default.
• W3007490411 cites W2111033751 @default.
• W3007490411 cites W2111626127 @default.
• W3007490411 cites W2114676020 @default.
• W3007490411 cites W2131999276 @default.
• W3007490411 cites W2133936335 @default.
• W3007490411 cites W2142004396 @default.
• W3007490411 cites W2149188042 @default.
• W3007490411 cites W2149929102 @default.
• W3007490411 cites W2151922469 @default.
• W3007490411 cites W2158091876 @default.
• W3007490411 cites W2160150321 @default.
• W3007490411 cites W2161380727 @default.
• W3007490411 cites W2165561873 @default.
• W3007490411 cites W2206011989 @default.
• W3007490411 cites W2286086842 @default.
• W3007490411 cites W2290476995 @default.
• W3007490411 cites W2316883951 @default.
• W3007490411 cites W2477849047 @default.
• W3007490411 cites W2516091697 @default.
• W3007490411 cites W2533230523 @default.
• W3007490411 cites W2559832962 @default.
• W3007490411 cites W2565931538 @default.
• W3007490411 cites W2622882429 @default.
• W3007490411 cites W2790309692 @default.
• W3007490411 cites W2800321461 @default.
• W3007490411 cites W2883006609 @default.
• W3007490411 cites W2912058252 @default.
• W3007490411 cites W2946601185 @default.
• W3007490411 cites W2991673750 @default.
• W3007490411 cites W3000329666 @default.
• W3007490411 cites W4241388592 @default.
• W3007490411 doi "https://doi.org/10.20411/pai.v5i1.349" @default.
• W3007490411 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7104555" @default.
• W3007490411 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32258853" @default.
• W3007490411 hasPublicationYear "2020" @default.
• W3007490411 type Work @default.
• W3007490411 sameAs 3007490411 @default.
• W3007490411 citedByCount "8" @default.
• W3007490411 countsByYear W30074904112020 @default.
• W3007490411 countsByYear W30074904112021 @default.
• W3007490411 countsByYear W30074904112022 @default.
• W3007490411 crossrefType "journal-article" @default.
• W3007490411 hasAuthorship W3007490411A5000090464 @default.
• W3007490411 hasAuthorship W3007490411A5002807035 @default.
• W3007490411 hasAuthorship W3007490411A5003036878 @default.
• W3007490411 hasAuthorship W3007490411A5017412054 @default.
• W3007490411 hasAuthorship W3007490411A5027237191 @default.
• W3007490411 hasAuthorship W3007490411A5038678361 @default.
• W3007490411 hasAuthorship W3007490411A5059681860 @default.
• W3007490411 hasAuthorship W3007490411A5064152130 @default.
• W3007490411 hasAuthorship W3007490411A5071905620 @default.
• W3007490411 hasAuthorship W3007490411A5074911675 @default.
• W3007490411 hasBestOaLocation W30074904111 @default.
• W3007490411 hasConcept C126322002 @default.
• W3007490411 hasConcept C142724271 @default.
• W3007490411 hasConcept C203014093 @default.
• W3007490411 hasConcept C2776247216 @default.
• W3007490411 hasConcept C2777575956 @default.
• W3007490411 hasConcept C2781069245 @default.
• W3007490411 hasConcept C71924100 @default.
• W3007490411 hasConcept C72563966 @default.
• W3007490411 hasConceptScore W3007490411C126322002 @default.
• W3007490411 hasConceptScore W3007490411C142724271 @default.
• W3007490411 hasConceptScore W3007490411C203014093 @default.
• W3007490411 hasConceptScore W3007490411C2776247216 @default.
• W3007490411 hasConceptScore W3007490411C2777575956 @default.
• W3007490411 hasConceptScore W3007490411C2781069245 @default.

• next